Your browser doesn't support javascript.
loading
Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo Evaluation in an MTAP Null Xenograft Model.
De Fusco, Claudia; Schimpl, Marianne; Börjesson, Ulf; Cheung, Tony; Collie, Iain; Evans, Laura; Narasimhan, Priyanka; Stubbs, Christopher; Vazquez-Chantada, Mercedes; Wagner, David J; Grondine, Michael; Sanders, Matthew G; Tentarelli, Sharon; Underwood, Elizabeth; Argyrou, Argyrides; Smith, James M; Lynch, James T; Chiarparin, Elisabetta; Robb, Graeme; Bagal, Sharan K; Scott, James S.
  • De Fusco C; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Schimpl M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Börjesson U; Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.
  • Cheung T; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Collie I; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Evans L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Narasimhan P; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Stubbs C; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Vazquez-Chantada M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Wagner DJ; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Grondine M; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Sanders MG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Tentarelli S; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.
  • Underwood E; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Argyrou A; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Smith JM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Lynch JT; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Chiarparin E; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Robb G; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
  • Scott JS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
J Med Chem ; 64(10): 6814-6826, 2021 05 27.
Article en En | MEDLINE | ID: mdl-33900758
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diseño de Fármacos / Inhibidores Enzimáticos / Metionina Adenosiltransferasa Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diseño de Fármacos / Inhibidores Enzimáticos / Metionina Adenosiltransferasa Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article